Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BG 00011

Drug Profile

BG 00011

Alternative Names: BG-00011; STX-100

Latest Information Update: 03 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biogen Idec
  • Developer Biogen
  • Class Antifibrotics; Monoclonal antibodies
  • Mechanism of Action Integrin alphaVbeta6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fibrosis; Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Idiopathic pulmonary fibrosis

Most Recent Events

  • 16 Sep 2019 Biogen terminates the phase II SPIRIT trial in Idiopathic pulmonary fibrosis (In the elderly, In adults) in USA, Argentina, Belgium, Chile, Czech Republic, Denmark, France, Greece, Israel, Italy, Netherlands, Poland, Russia, Spain, United Kingdom, South Korea, Germany (SC), due to safety concerns (NCT03573505)
  • 17 May 2019 Efficacy data from a phase IIa trial in Idiopathic pulmonary fibrosis presented at the 115th International Conference of the American Thoracic Society (ATS-2019)
  • 21 Sep 2018 Phase-II clinical trials in Idiopathic pulmonary fibrosis (In the elderly, In adults) in Australia (SC) (NCT03573505)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top